MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Munshi, Saif Ullah ^a,d   Panda, Harekrushna ^b   Holla, Prasida ^a   Rewari, Bharat Bhushan ^c   Jameel, Shahid ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY ICGEB   (India)

^c DR RAM MANOHAR LOHIA HOSPITAL   (India)

^d BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; MICRORNA; MICRORNA 146B 5P; MICRORNA 150; MICRORNA 16; MICRORNA 191; MICRORNA 223; NEVIRAPINE; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE; BENZOXAZINE DERIVATIVE; BIOLOGICAL MARKER; MIRN146 MICRORNA, HUMAN; MIRN150 MICRORNA, HUMAN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG TREATMENT FAILURE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA ISOLATION; VIRUS LOAD; ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; FEMALE; GENE EXPRESSION REGULATION; HIV; HUMANS; LAMIVUDINE; LEUKOCYTES, MONONUCLEAR; MALE; MICRORNAS; NEVIRAPINE; STAVUDINE; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 84901312523     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095920     Document Type: Article

References (49)

1. Tsoukas CM, Bernard NF (1994) Markers predicting progression of human immunodeficiency virus-related disease. Clin Microbiol Rev 7: 14-28. (Pubitemid 24038087)
2. Gupta V, Gupta S (2004) Laboratory markers associated with progression of HIV infection. Indian J Med Microbiol 22: 7-15. (Pubitemid 38292459)
3. Kanekar A (2010) Biomarkers predicting progression of human immunodeficiency virus-related disease. J Clin Med Res 2: 55-6.
4. Kawado M, Hashimoto S, Yamaguchi T, Oka S, Yoshizaki K, et al (2006) Difference of progression to AIDS according to CD4 cell count, plasma HIV RNA level and the use of antiretroviral therapy among HIV patients infected through blood products in Japan. J Epidemiol 16: 101-6. (Pubitemid 43796770)
5. Moore DM, Awor A, Downing R, Kaplan J, Montaner JS, et al (2008) CD4+ T-cell count monitoring does not accurately identify HIV infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr 49: 477-484.
6. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20. (Pubitemid 40094598)
7. Witwer KW, Watson AK, Blankson JN, Clements JE (2012) Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV-1-infected elite suppressors and viremic patients. Retrovirology 9: 5.
8. Swaminathan S, Zaunders J, Wilkinson J, Suzuki K, Kelleher AD (2009) Does the presence of anti-HIV miRNAs in monocytes explain their resistance to HIV-1 infection? Blood 113: 5029-30.
9. Wang X, Ye L, Hou W, Zhou Y, Wang YJ, et al (2009) Cellular microRNA expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection. Blood 113: 671-674.
10. Houzet L, Yeung M, Lame V, Desai D, Smith SM, et al (2008) MicroRNA profile changes in human immunodeficiency virus type 1 (HIV-1) seropositive individuals. Retrovirology 5: 118.
11. Huang J, Wang F, Argyris E, Chen K, Liang Z, et al (2007) Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med 13: 1241-1247. (Pubitemid 47530631)
12. Corbeau P (2008) Interfering RNA and HIV: reciprocal interferences. PLoS Pathog 4(9):e1000162.
13. Triboulet R, Mari B, Lin YL, Chable-Bessia C, Bennasser Y, et al (2007) Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science 315: 1579-1582. (Pubitemid 46449475)
14. Flynt AS, Lai EC (2008) Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat Rev Genet 9: 831-842.
15. Baltimore D, Boldin MP, O'Connell RM, Rao DS, Taganov KD (2008) MicroRNAs: new regulators of immune cell development and function. Nat Immunol 9: 839-845. (Pubitemid 352038302)
16. Cortez A, Calin GA (2009) MicroRNA identification in plasma and serum: a novel tool to diagnose and monitor diseases. Expert Opin Biol Ther. 9:703-711.
17. Visone R, Veronese A, Rassenti LZ, Balatti V, Pearl DK, et al (2011) miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood 118: 3072-9.
18. Fayyad-Kazan H, Bitar N, Najar M, Lewalle P, Fayyad-Kazan M, et al (2013) Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med 11: 31.
19. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, et al (2009) Circulating microRNAs, potential biomarkers for drug-induced liver injury Proc. Natl. Acad. Sci. U.S.A. 106: 4402-4407.
20. Waidmann O, Bihrer V, Pleli T, Farnik H, Berger A, et al (2012) Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J Viral Hepat. 19(2): e58-65.
21. Bihrer V, Friedrich-Rust M, Kronenberger B, Forestier N, Haupenthal J, et al (2011) Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol 106:1663-9.
22. Adachi T, Nakanishi M, Otsuka Y, Nishimura K, Hirokawa G, et al (2010) Plasma microRNA 499 as a biomarker of acute myocardial infarction. Clin Chem. 56: 1183-1185.
23. Swaminathan S, Suzuki K, Seddiki N, Kaplan W, Cowley MJ, et al (2012) Differential regulation of the Let-7 family of microRNAs in CD4+ T cells alters IL-10 expression. J Immunol 188: 6238-46.
24. Kamat A, Ravi V, Desai A, Satishchandra P, Satish KS, et al (2007) Quantitation of HIV-1 RNA levels in plasma and CSF of asymptomatic HIV-1 infected patients from South India using a TaqMan real time PCR assay. J Clin Virol 39: 9-15. (Pubitemid 46575337)
25. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108. (Pubitemid 351818697)
26. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-(Delta C (T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
27. Liu AM, Yao TJ, Wang W, Wong KF, Lee NP, et al (2012) Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open. 2(2): e 0008.
28. Reid G, Kirschner MB, van Zandwijk N. (2011) Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 80: 193-208.
29. Yu J, Ohuchida K, Mizumoto K, Sato N, Kayashima T, et al (2010) MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer 9: 169.
30. Swets J A (1988) Measuring the accuracy of diagnostic systems. Science 240: 1285-1293.
31. Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J (2010) The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol 84: 1-16.
32. Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, et al (2007) Wang J, Rajewsky N, Bender TP, Rajewsky K. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 131: 146-59. (Pubitemid 47498525)
33. De Milito A, Nilsson A, Titanji K, Thorstensson R, Reizenstein E, et al (2004) Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 103: 2180-6. (Pubitemid 38326236)
34. Duskova K, Nagilla P, Le H-S, Iyer P, Thalamuthu A, et al (2013) MicroRNA regulation and its effects on cellular transcriptome in Human Immunodeficiency Virus-1 (HIV-1) infected individuals with distinct viral load and CD4 cell counts. BMC Infectious Diseases 13: 250.
35. Ghisi M, Corradin A, Basso K, Frasson C, Serafin V, et al (2011) Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood. 117: 7053-62.
36. Wu H, Neilson JR, Kumar P, Manocha M, Shankar P, et al (2007) miRNA Profiling of Naïve, Effector and Memory CD8 T Cells. PLoS ONE 2(10): e1020.
37. Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF (2007) miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci U S A 104: 7080-7085. (Pubitemid 47186012)
38. Bagasra O, Hauptman SP, Lischner HW, Sachs M, Pomerantz RJ (1992) Detection of human immunodeficiency virus type 1 provirus in mononuclear cells by insitu polymerase chain reaction. N Engl J Med 326: 1385-1391.
39. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 12: 1365-71. (Pubitemid 44924494)
40. Schmidt WM, Spiel AO, Jilma B, Wolzt M, Muller M (2009) In vivo profile of the human leukocyte microRNA response to endotoxemia. Biochem Biophys Res Commun 380: 437-441.
41. Chen X, Ba Y, Ma L, Cai X, Yin Y, et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006.
42. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, et al (2011) Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128: 608-616.
43. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, et al (2009) Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58: 1375-1381.
44. Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, et al (2011) MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 6:e25787.
45. Chen X, Liang H, Zhang J, Zen K, Zhang CY (2012) Horizontal transfer of microRNAs: molecular mechanisms and clinical applications. Protein Cell. 3: 28-37.
46. Van Veldhoven PP, Matthews TJ, Bolognesi DP, Bell RM (1992) Changes in bioactive lipids, alkylacylglycerol and ceramide, occur in HIV-infected cells. Biochem Biophys Res Commun 187: 209-16.
47. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, et al (2010) Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 285: 17442-17452.
48. Haughey NJ, Cutler RG, Tamara A, McArthur JC, Vargas DL, et al (2004) Perturbation of Sphingolipid Metabolism and Ceramide Production in HIV-Dementia Ann Neurol. 55: 257-267. (Pubitemid 38167003)
49. Singh I, Pahan K, Khan M, Singh AK (1998) Cytokine-mediated induction of ceramide production is redox-sensitive. Implications to proinflammatory cytokine-mediated apoptosis in demyelinating diseases. J Biol Chem 273: 20354-62. (Pubitemid 28377600)